What is HC Wainwright’s Forecast for SNDX FY2025 Earnings?

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) – HC Wainwright dropped their FY2025 earnings per share estimates for shares of Syndax Pharmaceuticals in a research report issued to clients and investors on Tuesday, March 4th. HC Wainwright analyst E. White now forecasts that the company will post earnings of ($3.86) per share for the year, down from their prior estimate of ($3.76). HC Wainwright currently has a “Buy” rating and a $51.00 target price on the stock. The consensus estimate for Syndax Pharmaceuticals’ current full-year earnings is ($3.72) per share. HC Wainwright also issued estimates for Syndax Pharmaceuticals’ FY2026 earnings at ($2.97) EPS.

Several other equities research analysts have also weighed in on the company. Citigroup reduced their price objective on Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating for the company in a research note on Tuesday. The Goldman Sachs Group increased their price target on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Scotiabank dropped their price target on Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating on the stock in a research note on Wednesday, January 8th. StockNews.com lowered shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 23rd. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Syndax Pharmaceuticals from $35.00 to $39.00 and gave the stock an “overweight” rating in a research report on Tuesday. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $36.00.

Syndax Pharmaceuticals Stock Performance

Shares of NASDAQ:SNDX opened at $14.29 on Thursday. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of -3.94 and a beta of 0.90. Syndax Pharmaceuticals has a 1-year low of $12.06 and a 1-year high of $25.16. The company has a 50 day moving average price of $14.31 and a 200 day moving average price of $16.68.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.79). The firm had revenue of $7.68 million for the quarter, compared to the consensus estimate of $86.32 million.

Insider Transactions at Syndax Pharmaceuticals

In other Syndax Pharmaceuticals news, CEO Michael A. Metzger sold 13,288 shares of the stock in a transaction on Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $205,964.00. Following the transaction, the chief executive officer now directly owns 300,121 shares of the company’s stock, valued at $4,651,875.50. This represents a 4.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Keith A. Goldan sold 3,777 shares of the company’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $58,543.50. Following the sale, the chief financial officer now owns 90,746 shares of the company’s stock, valued at approximately $1,406,563. This trade represents a 4.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 21,683 shares of company stock worth $336,087 in the last 90 days. 4.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Assenagon Asset Management S.A. increased its stake in shares of Syndax Pharmaceuticals by 343.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 2,064,456 shares of the company’s stock worth $27,292,000 after purchasing an additional 1,598,428 shares during the period. Soleus Capital Management L.P. increased its position in Syndax Pharmaceuticals by 128.4% in the 4th quarter. Soleus Capital Management L.P. now owns 2,492,000 shares of the company’s stock worth $32,944,000 after buying an additional 1,401,016 shares during the period. Octagon Capital Advisors LP acquired a new position in shares of Syndax Pharmaceuticals during the fourth quarter worth approximately $11,951,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new stake in shares of Syndax Pharmaceuticals in the third quarter valued at approximately $15,165,000. Finally, Eventide Asset Management LLC bought a new stake in shares of Syndax Pharmaceuticals in the third quarter valued at approximately $15,150,000.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).